Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.40 |
| ▸ | TUBB | P07437 | 3/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18054350 | 0.81 | RHEB (0.43) | RHEBMAPTALDH1A1KDM4ERXFP1 | |
| SCHEMBL17170039 | 0.81 | RHEB (0.43) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15704612 | 0.79 | PRKCQ (0.42) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30637856 | 0.78 | TUBB4A (0.40) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15704600 | 0.78 | TUBB4A (0.40) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL21831849 | 0.78 | ALDH1A1 (0.45) | RHEBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL18527173 | 0.76 | RHEB (0.47) | RHEBMAPTALDH1A1KDM4ERXFP1 | |
| SCHEMBL18054260 | 0.75 | NOTUM (0.50) | TUBB1MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL13957837 | 0.75 | RHEB (0.44) | RHEBMAPTLMNAHTR1AHTR6 | |
| SCHEMBL18876105 | 0.75 | RHEB (0.42) | RHEBMAPTALDH1A1KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3261638-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIO, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9550760-B2 | Substituted indol-5-ol derivatives and their therapeutic applications | NANTBIOSCIENCE, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| WO-2016138527-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. | 2016-01-21 | — | — | US | disclosed |
| WO-2014071378-A9 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014145403-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | NANTBIO, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014071378-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189400-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | RHEB 821/4885TUBB4A 1196/4885TUBB 660/4885 |
| US-20170088544-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | GRK5, GRK3, MTMR1 | RHEB 751/4885TUBB4A 1127/4885TUBB 590/4885 |
| US-20160016945-A1 | SUBSTITUTED INDOL-5-OL DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | GRK5, GRK3, CDK5 | RHEB 821/4885TUBB4A 1196/4885TUBB 660/4885 |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | RHEB 2914/4885TUBB4A 2896/4885TUBB 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.